C4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3, at the American Association for Cancer Research (AACR) Annual Meeting

Rhea-AI Summary

C4 Therapeutics, Inc. (Nasdaq: CCCC) announced that a late-breaking abstract featuring preclinical data for its protein degrader CFT7455 has been selected for presentation at the AACR 2021 Annual Meeting, scheduled for April 10-15, 2021. CFT7455 targets IKZF1/3 to treat hematologic malignancies and has demonstrated potent tumor regression in IMiD-resistant multiple myeloma models. This signifies a key milestone for C4T in advancing innovative cancer treatments through targeted protein degradation, potentially overcoming limitations of traditional therapies.

Positive

• CFT7455 shows potent tumor regression in preclinical models, indicating strong therapeutic potential.
• Presentation at AACR 2021 enhances visibility and credibility in the oncological research community.

Negative

• None.

WATERTOWN, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that a late-breaking abstract featuring preclinical data for CFT7455 has been selected for presentation at the first session of the American Association for Cancer Research (AACR) 2021 Annual Meeting, being held virtually April 10-15, 2021. CFT7455, the Company’s most advanced protein degrader, targets IKZF1/3 for the treatment of hematologic malignancies.

Abstract Presentation Details

• Abstract: 5446
• Title: CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models 
• Session: Late-Breaking Mini-symposium 1
• Session Time: 1:30 p.m. ET on Saturday, April 10, 2021
• Presenter: David Proia, Ph.D., Senior Director, In Vivo Pharmacology at C4T
  

About C4 Therapeutics
C4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.

FAQ

What is CFT7455 and its significance for C4 Therapeutics?

CFT7455 is a novel protein degrader targeting IKZF1/3, showing promise for treating hematologic malignancies, particularly in cases resistant to existing treatments.

When will CFT7455 be presented at the AACR 2021 Annual Meeting?

CFT7455 will be presented on April 10, 2021, at 1:30 p.m. ET during the Late-Breaking Mini-symposium 1.

What are the potential advantages of CFT7455 over traditional therapies?

CFT7455's targeted protein degradation approach could reduce drug resistance, improve potency, and decrease side effects compared to conventional treatments.

Who is presenting the CFT7455 abstract at the AACR?

The abstract will be presented by David Proia, Ph.D., Senior Director of In Vivo Pharmacology at C4 Therapeutics.